Show source-provided references
1. Agreement between skeletal muscle mass measurements using computed tomography imaging and magnetic resonance imaging in head and neck cancer patients
10.1016/j.oraloncology.2019.06.022 ↗2. The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy
10.1007/s00405-020-05972-2 ↗3. Chargi, N., Wegner, I., Markazi, N., Smid, E., de Jong, P., Devriese, L., and de Bree, R. (2021). Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy. J. Clin. Med., 10.
10.3390/jcm10081762 ↗4. Huiskamp, L.F.J., Chargi, N., Devriese, L.A., May, A.M., Huitema, A.D.R., and de Bree, R. (2020). The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis. J. Clin. Med., 9.
10.3390/jcm9113780 ↗5. The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin
10.1002/hed.26919 ↗6. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer
10.1007/s00405-021-07229-y ↗7. Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap
10.1016/j.oraloncology.2019.104530 ↗8. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer
10.1016/j.oraloncology.2017.05.012 ↗9. The effect of skeletal muscle mass on dose-limiting toxicities during (chemo)radiotherapy in patients with head and neck cancer: A systematic review and meta-analysis
10.1016/j.oraloncology.2024.106978 ↗10. Interobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical vertebra
10.1007/s00405-019-05307-w ↗14. Diagnosis of Sarcopenia in Head and Neck Computed Tomography: Cervical Muscle Mass as a Strong Indicator of Sarcopenia
10.21053/ceo.2018.01613 ↗16. Skeletal muscle mass at C3 is a strong predictor for skeletal muscle mass at L3 in sarcopenic and non-sarcopenic patients with head and neck cancer
10.1016/j.oraloncology.2021.105558 ↗17. Huang, W., Tan, P., Zhang, H., Li, Z., Lin, H., Wu, Y., Du, Q., Wu, Q., Cheng, J., and Liang, Y. (2022). Skeletal Muscle Mass Measurement Using Cone-Beam Computed Tomography in Patients with Head and Neck Cancer. Front. Oncol., 12.
10.3389/fonc.2022.902966 ↗23. de Vet, H., Terwee, C., Mokkink, L., and Knol, D. (2011). Measurement in Medicine: A Practical Guide, Cambridge University Press. [1st ed.].
10.1017/CBO9780511996214 ↗25. Quantifying Test-Retest Reliability Using the Intraclass Correlation Coefficient and the SEM
26. Change of skeletal muscle mass and associated factors during radiotherapy and chemoradiotherapy in patients with head and neck squamous cell carcinoma
10.1016/j.oor.2025.100737 ↗